1,123 results on '"Planchard, D."'
Search Results
152. P84.01 The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.
153. OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
154. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
155. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC
156. FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study
157. P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
158. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique
159. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France
160. OA03.07 Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study
161. 75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)
162. Cancer broncho-pulmonaire chez le non-fumeur
163. Cancer bronchique à petites cellules : principes et traitements
164. Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
165. 42P Pleural effusion is a negative prognostic factor for immunotherapy in non small cell lung cancer (NSCLC): The PLUIE study
166. 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
167. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms
168. 1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC
169. 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
170. LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
171. 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
172. 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
173. 1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
174. 1377P Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC
175. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
176. Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients
177. RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
178. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)
179. Le syndrome d’apnées du sommeil du sujet âgé
180. STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma
181. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients
182. Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas
183. Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)[P1.04-31]
184. Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients [MA25.03]
185. 1731P Lung cancer predisposition in Li-Fraumeni syndrome: Cohort from Gustave Roussy Institute
186. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
187. Corrigendum: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv192–iv237) DOI: 10.1093/annonc/mdy275)
188. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients
189. Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated
190. OA03.08 Clinical Utility of CTDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients
191. ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION
192. Three-year overall survival update from the PACIFIC trial
193. Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas
194. Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC
195. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
196. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
197. A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
198. MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer
199. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
200. P1.10-06 Pathological Characterization of Radon-Induced Lung Cancer in Rats
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.